Pathophysiology
(2 contents)
Pathophysiology
Diabetes pathophysiology
ENG, SPA, Ger, FRE
Dr Inzucchi discusses the eight abnormalities leading to diabetes mellitus, the “Ominous Octet”, and current pathophysiologically-based therapies aimed at glycaemic control and prevention of vascular complications in type 2 diabetes.
Pathophysiology
The incretin system & incretin-targeting agents
ENG, SPA, Ger, FRE
Dr Inzucchi explains how malfunction of incretin hormones leads to type 2 diabetes pathogenesis, and discusses the use of incretin-based treatments, in particular GLP-1 RAs, for diabetes management especially in patients with CVD.
Clinical inertia
(2 contents)
Clinical inertia
Therapeutic inertia in T2DM
ENG, SPA, Ger, FRE
Clinical inertia
Early glycaemic control in T2DM
ENG, SPA, Ger, FRE
Prof Khunti highlights the importance of screening and early intensification of antihyperglycaemic agents for better glycaemic control and improved microvascular, macrovascular and mortality outcomes in patients with type 2 diabetes.
Incretin-based glycaemic control
(4 contents)
Incretin-based drugs
The use of GLP-1 RAs in T2DM
ENG, SPA, Ger, FRE
Incretin-based drugs
Incretin-based drugs: What does the data say?
ENG, SPA, Ger, FRE
Dr Davies highlights the role of the incretin system in glycaemic control and major differences between GLP-1RAs and DPP-4is and explores recent data from meta-analyses and head-to-head trials on the efficacy of these drug classes
Incretin-based drugs
Incretin-based drugs: Mode of action/delivery & dosing schedule
ENG, SPA, Ger, FRE
Su Down underlines the role of incretin hormones in regulating glucose haemostasis and describes the mode of action/delivery and dosing schedule of incretin-based therapies through which, the glycemic control in type 2 diabetes is maintained.
Incretin-based drugs
Appropriate prescribing practices
ENG, SPA, FRE, Ger
Su Down provides insight into the special considerations for safe prescribing of GLP-RAs and DPP-4is, as she describes appropriate patient populations, dose titration, sick day rules, and management of potential adverse events.
Beyond glycaemic control
(2 contents)
Beyond Glycaemic Control
Cardiovascular benefits
ENG, SPA, FRE, Ger
Dr Kosiborod highlights the recent data on the role of GLP-1 RAs in cardiovascular risk reduction and shares his own experience of how a multidisciplinary approach can maximise guideline-directed care, including the adoption of GLP-1 RAs.
Beyond Glycaemic Control
Weight loss benefits
ENG, SPA, FRE, Ger
Dr Kosiborod discusses the importance of obesity management in type 2 diabetes and which anti-diabetic agents have proven weight loss benefits. He also highlights the key findings from the STEP trial programme.
